CMS head Chiquita Brooks-LaSure says the agency expects to keep covering drugs that the FDA approves through its fast-track accelerated approval pathway, despite its recent decision on Biogen's Aduhelm.

The top executive at McKinsey appeared for the first time before Congress to answer for the consulting firm’s role in fanning the opioid crisis.

Rite Aid was ordered to pay nearly $123 million to Humana for allegedly seeking inflated reimbursements for prescription drugs.

The Biden administration announced a series of initiatives aimed at increasing the use of antiviral pills to treat Covid-19, with a focus on Pfizer's Paxlovid.

Parents and doctors now have more tools than ever to help kids manage symptoms of ADHD. But are these new drugs and devices any better than what’s come before?

Staff at U.S. health agencies fail to report suspected political interference that is inappropriately influencing government policymaking.

Thanks to Covid-19 vaccines and therapies, U.S. spending on pharmaceuticals rose 12% in 2021 as usage reached record levels and new prescriptions largely recovered from the pandemic slowdown.

Several hundred GlaxoSmithKline workers have voted to go on strike after rejecting a below-inflation pay raise, setting the stage for a labor battle unusual in the pharmaceutical industry.

Worldwide demand for the Pfizer Covid-19 antiviral pill has been unexpectedly light due to eligibility requirements, reduced testing, and potential drug interactions.

The U.K. medicines watchdog agency is being urged to strengthen its conflict of interest policy after it was disclosed that six of its board members are receiving payments from pharma…

The head of the World Trade Organization says negotiations on an intellectual property proposal for Covid-19 vaccines are "trying to iron out the last things."

Bausch Health is being investigated by U.S. authorities in connection with marketing of four medicines used to treat skin conditions.

Amid rising concern over antimicrobial resistance, the U.K. has taken a major step toward becoming the first country to launch an experimental payment model for antibiotics.

Biogen and other drugmakers have already hinted they might sue Medicare over its decision to limit coverage for the controversial new Alzheimer's drug Aduhelm.

Eisai and Eli Lilly still plan to seek accelerated approval for Alzheimer's drugs even after CMS severely limited coverage of medicines approved under the controversial program.

Medicare finalized its plan to restrict coverage for the controversial, pricey Alzheimer’s treatment Aduhelm to patients participating in clinical trials.

Many lower-income Medicare Part D beneficiaries who do not receive subsidies — which can cap or lower out-of-pocket costs — did not fill their prescriptions.

A new survey by STAT and The Harris Poll finds 6 in 10 Americans have already decided they will get another Covid booster shot if it’s recommended for them.

Bluebird Bio is reducing expenses and laying off nearly a third of its employees to preserve cash ahead of two pivotal gene-therapy approval decisions expected later this year.

Novartis is simplifying its structure as part of plans to save $1 billion in costs by 2024 and strengthen its business in the U.S.

Among those over 50, 15% aren't fully vaccinated and 50% haven't received a booster. Protecting those at greatest risk requires more federal funding.

In advance of a World Health Assembly meeting, the U.K. is circulating a resolution that outlines goals for improving clinical trials quality.

Roche disclosed that an experimental cancer immunotherapy directed against a target called TIGIT failed to slow the progression of a less common but aggressive type of lung cancer.

Pfizer employees are frustrated and angry over a payroll mistake that could force them to give back money some have already spent.

U.S. Sen. Tim Scott of South Carolina, a rising star in the Republican Party, is getting showered with pharmaceutical industry money before facing voters this fall.

Researchers and drugmakers are turning to finding a cure for long Covid, a more elusive target than vaccines and treatments for acute infection.

The Food and Drug Administration declined to approve an Eli Lilly (LLY) lung cancer drug that had been studied only in China.

Moderna will ask the U.S. Food and Drug Administration to authorize its Covid-19 vaccine for emergency use in children aged 6 months to 6 years.

Al Sandrock, the top Biogen scientist who exited last year in a dispute over its controversial Alzheimer’s drug, was named CEO of Voyager Therapeutics.

The prospects for would-be Covid-19 vaccine manufacturers to prove their shots are protective are becoming ever slimmer.